• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国生物假体的临床应用:现状与未来。

Clinical Application of Bioprosthesis in China: Current Status and Future.

机构信息

Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

出版信息

Curr Med Sci. 2019 Aug;39(4):523-525. doi: 10.1007/s11596-019-2068-5. Epub 2019 Jul 25.

DOI:10.1007/s11596-019-2068-5
PMID:31346985
Abstract

China is one of the countries which have a high incidence of heart valvular disease, but the use of biological valve is limited in China before because the majority of patients are young patients suffering from rheumatic heart disease. The biological valve has a good application prospect in China. On the one hand, the new generation of biological valves have been significantly improved in the aspects of anti-calcification treatment, anti-metabolism, material quality control, valve frame mechanics design, and leaflet sewing technology, and the application effect is improved; on the other hand, surgeons should adapt to the new concept changes, and correctly understand and rationally apply biological valves, master valve repair, atrial fibrillation ablation and other techniques, combined with interventional, minimally invasive techniques, etc., according to the specific conditions of the disease and choose the surgery type to ensure the patients' long-term life quality.

摘要

中国是心脏瓣膜病发病率较高的国家之一,但在过去,由于大多数患者是患有风湿性心脏病的年轻患者,生物瓣膜在中国的应用受到限制。生物瓣膜在中国具有良好的应用前景。一方面,新一代生物瓣膜在抗钙化处理、抗代谢、材料质量控制、瓣架力学设计和瓣叶缝制技术等方面有了显著的改进,应用效果得到了提高;另一方面,外科医生应适应新理念的变化,正确理解和合理应用生物瓣膜,掌握瓣膜修复、房颤消融等技术,并结合介入、微创等技术,根据具体病情选择手术类型,以保证患者的长期生活质量。

相似文献

1
Clinical Application of Bioprosthesis in China: Current Status and Future.中国生物假体的临床应用:现状与未来。
Curr Med Sci. 2019 Aug;39(4):523-525. doi: 10.1007/s11596-019-2068-5. Epub 2019 Jul 25.
2
Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.心房颤动合并心脏瓣膜异常患者的卒中预防策略:对“瓣膜性”心房颤动的认知:欧洲心律协会调查结果
Europace. 2016 Oct;18(10):1593-1598. doi: 10.1093/europace/euw302.
3
The state of surgical ablation for atrial fibrillation in patients with mitral valve disease.二尖瓣疾病患者心房颤动的外科消融治疗现状。
Curr Opin Cardiol. 2013 Mar;28(2):170-80. doi: 10.1097/HCO.0b013e32835ced9c.
4
Catheter ablation for atrial fibrillation after an unsuccessful surgical ablation and biological prosthetic mitral valve replacement: a pilot study.外科消融术失败及生物人工二尖瓣置换术后房颤的导管消融:一项初步研究
J Chin Med Assoc. 2014 Aug;77(8):409-15. doi: 10.1016/j.jcma.2014.01.012. Epub 2014 Aug 7.
5
[Ablation of the orifices of the pulmonary veins under direct vision by using the transballoon ultrasound ablation catheter for permanent atrial fibrillation with rheumatic valve disease].经皮球囊超声消融导管直视下肺静脉口消融治疗风湿性瓣膜病合并永久性心房颤动
Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Feb;35(2):123-6.
6
Valve replacement surgery for older individuals with preoperative atrial fibrillation: the effect of prosthetic valve choice and surgical ablation.老年患者术前心房颤动的瓣膜置换手术:人工瓣膜选择和外科消融的影响。
J Thorac Cardiovasc Surg. 2014 Jun;147(6):1907-17. doi: 10.1016/j.jtcvs.2013.07.019. Epub 2013 Aug 28.
7
Efficiency of radiofrequency ablation for surgical treatment of chronic atrial fibrillation in rheumatic valvular disease.射频消融术在风湿性瓣膜病慢性心房颤动外科治疗中的疗效
Int J Cardiol. 2014 Jul 1;174(3):497-502. doi: 10.1016/j.ijcard.2014.03.153. Epub 2014 Mar 29.
8
The significance of atrial fibrillation ablation in patients undergoing mitral valve surgery.二尖瓣手术患者中行心房颤动消融的意义。
Semin Thorac Cardiovasc Surg. 2002 Jul;14(3):193-7. doi: 10.1053/stcs.2002.35290.
9
Atrial fibrillation ablation in patients undergoing aortic valve replacement.接受主动脉瓣置换术患者的心房颤动消融术
J Heart Valve Dis. 2012 May;21(3):350-7.
10
Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation.心房颤动消融术后行起搏器植入。
J Am Coll Cardiol. 2019 May 21;73(19):2427-2435. doi: 10.1016/j.jacc.2019.02.062.

引用本文的文献

1
Multimodality Cardiovascular Imaging for Totally Video-Guided Thorascopic Cardiac Surgery.用于全视频引导胸腔镜心脏手术的多模态心血管成像
Rev Cardiovasc Med. 2024 May 21;25(5):181. doi: 10.31083/j.rcm2505181. eCollection 2024 May.
2
Improved Cytocompatibility and Reduced Calcification of Glutaraldehyde-Crosslinked Bovine Pericardium by Modification With Glutathione.通过谷胱甘肽修饰提高戊二醛交联牛心包的细胞相容性并减少钙化
Front Bioeng Biotechnol. 2022 May 19;10:844010. doi: 10.3389/fbioe.2022.844010. eCollection 2022.
3
Yak Pericardium as an Alternative Biomaterial for Transcatheter Heart Valves.

本文引用的文献

1
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2017年美国心脏协会/美国心脏病学会对2014年《美国心脏协会/美国心脏病学会瓣膜性心脏病患者管理指南》的重点更新:美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289. doi: 10.1016/j.jacc.2017.03.011. Epub 2017 Mar 15.
2
A Systematic Review of Mitral Valve Repair With Autologous Pericardial Leaflet Augmentation for Rheumatic Mitral Regurgitation.自体心包瓣叶扩大术治疗风湿性二尖瓣反流的二尖瓣修复系统评价
Ann Thorac Surg. 2016 Oct;102(4):1400-5. doi: 10.1016/j.athoracsur.2016.04.009. Epub 2016 Jun 17.
3
牦牛心包作为经导管心脏瓣膜的替代生物材料。
Front Bioeng Biotechnol. 2021 Nov 8;9:766991. doi: 10.3389/fbioe.2021.766991. eCollection 2021.
4
Bioprosthetic vs mechanical mitral valve replacement for infective endocarditis in patients aged 50 to 69 years.50 岁至 69 岁患者感染性心内膜炎的生物瓣与机械瓣二尖瓣置换。
Clin Cardiol. 2020 Oct;43(10):1093-1099. doi: 10.1002/clc.23407. Epub 2020 Jun 4.
Mid- to long-term outcome comparison of the Medtronic Hancock II and bi-leaflet mechanical aortic valve replacement in patients younger than 60 years of age: a propensity-matched analysis.美敦力汉考克二代与双叶机械主动脉瓣置换术在60岁以下患者中的中长期疗效比较:倾向匹配分析
Interact Cardiovasc Thorac Surg. 2016 Mar;22(3):280-6. doi: 10.1093/icvts/ivv347. Epub 2015 Dec 15.
4
Mid- to Long-term Clinical Outcomes of Hancock II Bioprosthesis in Chinese Population.汉考克二代生物假体在中国人群中的中长期临床结果
Chin Med J (Engl). 2015 Dec 20;128(24):3317-23. doi: 10.4103/0366-6999.171424.
5
Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years.50-69 岁患者行主动脉瓣置换术:机械瓣与生物瓣的比较。
Eur Heart J. 2016 Sep 7;37(34):2658-67. doi: 10.1093/eurheartj/ehv580. Epub 2015 Nov 11.
6
National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements.机械瓣与生物瓣主动脉瓣置换术的使用情况及院内结局的全国趋势。
J Thorac Cardiovasc Surg. 2015 May;149(5):1262-9.e3. doi: 10.1016/j.jtcvs.2015.01.052. Epub 2015 Feb 11.
7
5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.经导管主动脉瓣置换术或主动脉瓣置换术治疗主动脉瓣狭窄高危患者的 5 年结果(PARTNER 1):一项随机对照试验。
Lancet. 2015 Jun 20;385(9986):2477-84. doi: 10.1016/S0140-6736(15)60308-7. Epub 2015 Mar 15.
8
Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry.经皮缘对缘二尖瓣修复术在 EVEREST(经血管缘对缘修复术)标准之外的扩展应用:GRASP(经皮夹植入术减少二尖瓣关闭不全)注册研究的 30 天和 12 个月临床及超声心动图结果。
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):74-82. doi: 10.1016/j.jcin.2014.07.024. Epub 2014 Dec 10.
9
Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old.机械瓣与生物瓣在<65 岁以下患者中的二尖瓣置换。
J Thorac Cardiovasc Surg. 2014 Jan;147(1):117-26. doi: 10.1016/j.jtcvs.2013.08.028. Epub 2013 Sep 27.
10
Tissue valve is the preferred option for patients aged 60 and older.对于60岁及以上的患者,组织瓣膜是首选选项。
Circulation. 2013 Sep 17;128(12):1365-71. doi: 10.1161/CIRCULATIONAHA.113.002584.